Involvement of tachykinins and NK1 receptor in the joint inflammation with collagen type II-specific monoclonal antibody-induced arthritis in mice

Journal of Nippon Medical School

Volumn 79, Issue 2, 2012, Pages 129-138

  Makino, Akira ^a   Sakai, Atsushi ^a   Ito, Hiromoto ^a   Suzuki, Hidenori ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Allodynia; Collagen antibody induced arthritis; Hemokinin 1; Receptor; Substance P

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; COLLAGEN ANTIBODY; HEMOKININ 1; INDOMETACIN; SUBSTANCE P; TACHYKININ; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; COLLAGEN TYPE 2; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUROKININ 1 RECEPTOR; PROTEIN PRECURSOR; TAC4 PROTEIN, MOUSE;

ALLODYNIA; ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; COLLAGEN ANTIBODY INDUCED ARTHRITIS; CONTROLLED STUDY; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPINAL CORD; SPINAL GANGLION; ANIMAL; DBA MOUSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; JOINT; METABOLISM; PATHOLOGY; TIME;

ANDROSTANES; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; BENZIMIDAZOLES; COLLAGEN TYPE II; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; HYPERALGESIA; INDOMETHACIN; INFLAMMATION; JOINTS; MALE; MICE; MICE, INBRED DBA; PROTEIN PRECURSORS; RECEPTORS, NEUROKININ-1; RNA, MESSENGER; SPINAL CORD; TACHYKININS; TIME FACTORS;

EID: 84859639678     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.79.129     Document Type: Article

References (57)

1. Bolon B, Stolina M, King C, et al: Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol 2011; 2011: 569068.
2. McDougall JJ: Arthritis and pain: neurogenic origin of joint pain. Arthritis Res Ther 2006; 8: 220.
3. Todd AJ: Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 2010; 11: 82336.
4. Douglas SD, Leeman SE: Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci 2011; 1217: 83-95.
5. Lam FY, Ferrell WR: Specific neurokinin receptors mediate plasma extravasation in the rat knee joint. Br J Pharmacol 1991; 103: 1263-1267.
6. Lam FY, Ferrell WR, Scott DT: Substance P-induced inflammation in the rat knee joint is mediated by neurokinin 1 (NK1) receptors. Regul Pept 1993; 46: 198-201.
7. Siney L, Brain SD: Involvement of sensory neuropeptides in the development of plasma extravasation in rat dorsal skin following thermal injury. Br J Pharmacol 1996; 117: 1065-1070.
8. Zhang Y, Berger A, Milne CD, Paige CJ: Tachykinins in the immune system. Curr Drug Targets 2006; 7: 1011-1020.
9. Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD: Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009; 30: 272-276.
10. Sluka KA, Milton MA, Willis WD, Westlund KN: Differential roles of neurokinin 1 and neurokinin 2 receptors in the development and maintenance of heat hyperalgesia induced by acute inflammation. Br J Pharmacol 1997; 120: 1263-1273.
11. Hong SK, Han JS, Min SS, et al: Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neurosci Lett 2002; 322: 21-24.
12. Denadai-Souza A, Camargo Lde L, Ribela MT, Keeble JE, Costa SK, Muscará MN: Participation of peripheral tachykinin NK 1 receptors in the carrageenan-induced inflammation of the rat temporomandibular joint. Eur J Pain 2009; 13: 812-819.
13. Lam FFY, Ng ESK: Substance P and glutamate receptor antagonists improve the anti-arthritic actions of dexamethasone in rats. Br J Pharmacol 2010; 159: 958-969.
14. Uematsu T, Sakai A, Ito H, Suzuki H: Intra-articular administration of tachykinin NK1 receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis. Eur J Pharmacol 2011; 668: 163-168.
15. Devillier P, Weill B, Renoux M, Menkès C, Pradelles P: Elevated levels of tachykinin-like immunoreactivity in joint fluids from patients with rheumatic inflammatory diseases. N Engl J Med 1986; 314: 1323.
16. Matucci-Cerinic M, Lombardi A, Leoncini G, et al: Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation? Rheumatol Int 1993; 13: 1-4.
17. Anichini M, Cesaretti S, Lepori M, Maddali Bongi S, Maresca M, Zoppi M: Substance P in the serum of patients with rheumatoid arthritis. Rev Rhum Engl Ed 1997; 64: 18-21.
18. Grimsholm O, Rantapää-Dahlqvist S, Forsgren S: Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R416-R426.
19. Kurtz MM, Wang R, Clements MK, et al: Identification, localization and receptor characterization of novel mammalian substance Plike peptides. Gene 2002; 296: 205-212.
20. Page NM: Hemokinins and endokinins. Cell Mol Life Sci 2004; 61: 1652-1663.
21. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ: Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 2000; 1: 392-397.
22. Duffy RA, Hedrick JA, Randolph G, et al: Centrally administered hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology 2003; 45: 242-250.
23. Nelson DA, Marriott I, Bost KL: Expression of hemokinin 1 mRNA by murine dendritic cells. J Neuroimmunol 2004; 155: 94-102.
24. Metwali A, Blum AM, Elliott DE, Setiawan T, Weinstock JV: Cutting edge: hemokinin has substance P-like function and expression in inflammation. J Immunol 2004; 172: 6528-6532.
25. -) influences the early stages of B lymphocyte development. Blood 2010; 116: 3792-3801.
26. Wang W, Li Q, Zhang J, et al: Hemokinin-1 activates the MAPK pathway and enhances B cell proliferation and antibody production. J Immunol 2010; 184: 3590-3597.
27. Liu L, Markus I, Saghire HE, Perera DS, King DW, Burcher E: Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1? Neurogastroenterol Motil 2011; 23: 475-e180.
28. Endo D, Ikeda T, Ishida Y, Yoshioka D, Nishimori T: Effect of intrathecal administration of hemokinin-1 on the withdrawal response to noxious thermal stimulation of the rat hind paw. Neurosci Lett 2006; 392: 114-117.
29. Watanabe C, Mizoguchi H, Yonezawa A, Sakurada S: Characterization of intrathecally administered hemokinin-1-induced nociceptive behaviors in mice. Peptides 2010; 31: 1613-1616.
30. Matsumura T, Sakai A, Nagano M, et al: Increase in hemokinin-1 mRNA in the spinal cord during the early phase of a neuropathic pain state. Br J Pharmacol 2008; 155: 767-774.
31. Nandakumar KS, Svensson L, Holmdahl R: Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 2003; 163: 1827837.
32. Hutamekalin P, Saito T, Yamaki K, et al: Collagen antibody-induced arthritis in mice: development of a new arthritogenic 5-clone cocktail of monoclonal antitype II collagen antibodies. J Immunol Methods 2009; 343: 49-55.
33. Kagari T, Doi H, Shimozato T: The importance of IL-1β-and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002; 169: 1459-1466.
34. Kagari T, Tanaka D, Doi H, Shimozato T: Essential role of Fcγ receptors in anti-type II collagen antibody-induced arthritis. J Immunol 2003; 170: 4318-4324.
35. Tanaka D, Kagari T, Doi H, Shimozato T: Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 2006; 119: 195-202.
36. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP: Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol 2007; 179: 4101-4109.
37. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110.
38. Kamei D, Yamakawa K, Takegoshi Y, et al: Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 2004; 279: 33684-33695.
39. Bley KR, Hunter JC, Eglen RM, Smith JAM: The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol Sci 1998; 19: 141-147.
40. McCoy JM, Wicks JR, Audoly LP: The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002; 110: 651-658.
41. Nagano M, Saitow F, Haneda E, Konishi S, Hayashi M, Suzuki H: Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey. Br J Pharmacol 2006; 147: 316-323.
42. Marchand JE, Wurm WH, Kato T, Kream RM: Altered tachykinin expression by dorsal root ganglion neurons in a rat model of neuropathic pain. Pain 1994; 58: 219-231.
43. Walker JS, Scott C, Bush KA, Kirkham BW: Effects of the peripherally selective κ-opioid asimadoline, on substance P and CGRP mRNA expression in chronic arthritis of the rat. Neuropeptides 2000; 34: 193-202.
44. Donaldson LF, Harmar AJ, McQueen DS, Seckl JR: Increased expression of preprotachykinin, calcitonin gene-related peptide, but not vasoactive intestinal peptide messenger RNA in dorsal root ganglia during the development of adjuvant monoarthritis in the rat. Mol Res Mol Brain Res 1992; 16: 143-149.
45. Garrett NE, Kidd BL, Cruwys SC, Tomlinson DR: Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of monoarthritic rats: comparison with changes in synovial substance P levels. Brain Res 1995; 675: 203-207.
46. Calzà L, Pozza M, Zanni M, Manzini CU, Manzini E, Hökfelt T: Peptide plasticity in primary sensory neurons and spinal cord during adjuvant-induced arthritis in the rat: an immunocytochemical and in situ hybridization study. Neuroscience 1998; 82: 575-589.
47. Basbaum AI: Spinal mechanisms of acute and persistent pain. Reg Anesth Pain Med 1999; 24: 59-67.
48. Snijdelaar DG, Dirksen R, Slappendel R, Crul BJP: Substance P. Eur J Pain 2000; 4: 121-135.
49. O'Shaughnessy MC, Vetsika EK, Inglis JJ, et al: The effect of substance P on nitric oxide release in a rheumatoid arthritis model. Inflamm Res 2006; 55: 236-240.
50. Binder W, Scott C, Walker JS: Involvement of substance P in the anti-inflammatory effects of the peripherally selective κ-opioid asimadoline and the NK1 antagonist GR205171. Eur J Neurosci 1999; 11: 2065-2072.
51. Goronzy JJ, Weyand CM: Rheumatoid arthritis. Immunol Rev 2005; 204: 55-73.
52. Bartok B, Firestein GS: Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-255.
53. Miyazawa S, Nishida K, Komiyama T, et al: Novel transdermal photodynamic therapy using ATXS10•Na(II) induces apoptosis of synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice. Rheumatol Int 2006; 26: 717-725.
54. Inoue H, Shimoyama Y, Hirabayashi K, et al: Production of neuropeptide substance P by synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Neurosci Lett 2001; 303: 149-152.
55. Menkes CJ, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F: Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1993; 20: 714-717.
56. Berger A, Tran AH, Paige CJ: Co-regulated decrease of neurokinin-1 receptor and hemokinin-1 gene expression in monocytes and macrophages after activation with pro-inflammatory cytokines. J Neuroimmunol 2007; 187: 83-93.
57. Klassert TE, Pinto F, Hernández M, et al: Differential expression of neurokinin B and hemokinin-1 in human immune cells. J Immunol 2008; 196: 27-34.